The latest price target for Dogwood Therapeutics (NASDAQ:DWTX) was reported by HC Wainwright & Co. on April 23, 2025. The analyst firm set a price target for $10.00 expecting DWTX to rise to within 12 months (a possible 84.33% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Dogwood Therapeutics (NASDAQ:DWTX) was provided by HC Wainwright & Co., and Dogwood Therapeutics upgraded their buy rating.

The last upgrade for Dogwood Therapeutics Inc happened on April 23, 2025 when HC Wainwright & Co. raised their price target to $10. HC Wainwright & Co. previously had a neutral for Dogwood Therapeutics Inc.

There is no last downgrade for Dogwood Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dogwood Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dogwood Therapeutics was filed on April 23, 2025 so you should expect the next rating to be made available sometime around April 23, 2026.

While ratings are subjective and will change, the latest Dogwood Therapeutics (DWTX) rating was a upgraded with a price target of $0.00 to $10.00. The current price Dogwood Therapeutics (DWTX) is trading at is $5.43, which is within the analyst’s predicted range.